Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Date publication

avril 2019

Journal

BJS open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRIGAND Cécile

Tous les auteurs :
Mercier F, Dagbert F, Pocard M, Goéré D, Quenet F, Wernert R, Dumont F, Brigand C, Passot G, Glehen O,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30957067

Résumé

Pseudomyxoma peritonei (PMP) is a rare clinical condition characterized by mucinous ascites, typically related to appendiceal or ovarian tumours. Current standard treatment involves cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), but recurrences occur in 20-30 per cent of patients. The aim of this study was to define the timing and patterns of recurrence to provide a basis for modifying follow-up of these patients.

Mots clés

Adult, Aged, Combined Modality Therapy, methods, Cytoreduction Surgical Procedures, methods, Disease-Free Survival, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, methods, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local, diagnosis, Peritoneal Neoplasms, mortality, Peritoneum, pathology, Prognosis, Prospective Studies, Pseudomyxoma Peritonei, mortality, Retrospective Studies, Time Factors

Référence

BJS Open. 2019 04;3(2):195-202